AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22731873 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (5 mg) every 4 hours for up to 10 days
Number of subjects: 282
Study 22731873 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo every 4 hours for up to 10 days
Number of subjects: 282
Study 22731873 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol (5 mg)
Number of subjects: 282
Study 22731873 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 282
Study 20176276 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence inspection
Number of subjects: 66
Study 20176276 — intervention group
Group type: COMPARATOR
Intervention: Standard panendoscopy
Number of subjects: 66
Study 18585835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2 g/d for 12 months
Number of subjects: 36
Study 18585835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 36
Study 15951467 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide coadministered with digoxin
Number of subjects: 18
Study 15951467 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin coadministered with azimilide
Number of subjects: 18
Study 12207874 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic bupivacaine (0.5% as salt)
Number of subjects: 6
Study 12207874 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐bupivacaine (0.5% as base)
Number of subjects: 6
Study 10367994 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI scales Pa, Sc and validity scale F
Number of subjects: 19
Study 10367994 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI scales Hs, D, and Hy
Number of subjects: 19
Study 10367994 — intervention group
Group type: COMPARATOR
Intervention: MMPI scales Hs, D and Hy in clinical remission
Number of subjects: 19
Study 10367994 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI scales Pd and Pt
Number of subjects: 19
Study 10367994 — intervention group
Group type: COMPARATOR
Intervention: MMPI scores in remission
Number of subjects: 19
Study 7585856 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention letters sent to physicians
Number of subjects: 190
Study 7585856 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians who did not receive letters)
Number of subjects: 190
Study 1969684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg bid
Number of subjects: 12
Study 1969684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg bid
Number of subjects: 12
Study 1969684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 495537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose diet
Number of subjects: 19
Study 495537 — intervention group
Group type: COMPARATOR
Intervention: Starch diet
Number of subjects: 19
Study 495537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 19
Study 31290569 — intervention group
Group type: EXPERIMENTAL
Intervention: R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles
Number of subjects: 62
Study 31290569 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 Y-ibritumomab tiuxetan
Number of subjects: 62
Study 31290569 — intervention group
Group type: EXPERIMENTAL
Intervention: R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine)
Number of subjects: 62
Study 28400132 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighting device (flashes at 100 cycles per minute)
Number of subjects: 22
Study 28400132 — intervention group
Group type: COMPARATOR
Intervention: No lighting device (control)
Number of subjects: 22
Study 25533307 — intervention group
Group type: EXPERIMENTAL
Intervention: Close Rectal Dissection (CRD)
Number of subjects: 59
Study 25533307 — intervention group
Group type: COMPARATOR
Intervention: Total Mesorectal Excision (TME)
Number of subjects: 59
Study 23658423 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 g/d 20:5n3 and 22:6n3 (1.51:1)
Number of subjects: 310
Study 23658423 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g/d 20:5n3 and 22:6n3 (1.51:1)
Number of subjects: 310
Study 23658423 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/d 20:5n3 and 22:6n3 (1.51:1)
Number of subjects: 310
Study 23658423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 21874260 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of branched-chain amino acids (BCAA; 12 g/day) and angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day)
Number of subjects: 0
Study 21874260 — intervention group
Group type: COMPARATOR
Intervention: BCAA (12 g/day)
Number of subjects: 0
Study 21874260 — intervention group
Group type: COMPARATOR
Intervention: ACE-I (perindopril; 4 mg/day)
Number of subjects: 0
Study 21874260 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 0
Study 19619146 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg daily
Number of subjects: 93
Study 19619146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 93
Study 16950506 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo axial
Number of subjects: 5
Study 16950506 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo gingival
Number of subjects: 5
Study 16950506 — intervention group
Group type: COMPARATOR
Intervention: In vitro axial
Number of subjects: 5
Study 16950506 — intervention group
Group type: COMPARATOR
Intervention: In vitro gingival
Number of subjects: 5
Study 15257378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g per day for 2 or 3 weeks
Number of subjects: 101
Study 12716812 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg o.d.)
Number of subjects: 54
Study 9988834 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrostep (20 microg ethinyl estradiol on days 1-5, 30 microg on days 6-12, 35 microg on days 13-21, and 1 mg norethindrone acetate throughout the cycle)
Number of subjects: 0
Study 9988834 — intervention group
Group type: COMPARATOR
Intervention: 30-microg ethinyl estradiol monophasic control drug
Number of subjects: 0
Study 9988834 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrostep
Number of subjects: 0
Study 9988834 — intervention group
Group type: COMPARATOR
Intervention: Triphasic control drug
Number of subjects: 0
Study 7483113 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 66 mg ferrous iron (as fumarate) daily
Number of subjects: 120
Study 7483113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 2317425 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified gas
Number of subjects: 42
Study 2317425 — intervention group
Group type: COMPARATOR
Intervention: Non-humidified gas
Number of subjects: 42
Study 7191315 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin (90 mg daily)
Number of subjects: 40
Study 7191315 — intervention group
Group type: COMPARATOR
Intervention: Tolmetin (600 mg daily)
Number of subjects: 40
Study 31915064 — intervention group
Group type: EXPERIMENTAL
Intervention: Morita therapy
Number of subjects: 16
Study 31915064 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 16
Study 30203308 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced version of parent-implemented Early Start Denver Model (P-ESDM) with motivational interviewing, multimodal learning tools, and weekly 1.5-h home visits for 12 weeks.
Number of subjects: 45
Study 30203308 — intervention group
Group type: COMPARATOR
Intervention: Basic model of parent-implemented Early Start Denver Model (P-ESDM) with 1.5 h of clinic-based parent coaching weekly for 12 weeks.
Number of subjects: 45
Study 30203308 — intervention group
Group type: EXPERIMENTAL
Intervention: Both enhanced and basic models of P-ESDM.
Number of subjects: 45
Study 30203308 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced version of P-ESDM.
Number of subjects: 45
Study 30203308 — intervention group
Group type: COMPARATOR
Intervention: Basic version of P-ESDM.
Number of subjects: 45
Study 25156040 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose beta-carotene (10 mg day(-1)) and vitamin C (500 mg day(-1))
Number of subjects: 46
Study 25156040 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 mg day(-1) of vitamin C)
Number of subjects: 46
Study 25156040 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose beta-carotene and vitamin C
Number of subjects: 46
Study 25156040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24504008 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention of home visitors in municipalities with high bonding social capital
Number of subjects: 4034
Study 24504008 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention of home visitors in municipalities with high linking social capital
Number of subjects: 4034
Study 22616927 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Carbamide Peroxide (CP) home-use
Number of subjects: 100
Study 22616927 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% Carbamide Peroxide (CP) home-use
Number of subjects: 100
Study 22616927 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% Hydrogen Peroxide (HP) in-office
Number of subjects: 100
Study 22616927 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% Hydrogen Peroxide (HP) in-office
Number of subjects: 100
Study 22616927 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 100
Study 19398325 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up
Number of subjects: 109
Study 19398325 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient clinic follow-up
Number of subjects: 109
Study 17558825 — intervention group
Group type: EXPERIMENTAL
Intervention: History of depression
Number of subjects: 677
Study 17558825 — intervention group
Group type: EXPERIMENTAL
Intervention: No history of depression
Number of subjects: 677
Study 17558825 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression history and depression-related measures
Number of subjects: 677
Study 17558825 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 677
Study 14759618 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal emergency contraception
Number of subjects: 0
Study 11352955 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-MVAC (high-dose-intensity chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin plus granulocyte colony-stimulating factor)
Number of subjects: 263
Study 11352955 — intervention group
Group type: COMPARATOR
Intervention: MVAC (classic chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 263
Study 11352955 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-MVAC
Number of subjects: 263
Study 11352955 — intervention group
Group type: COMPARATOR
Intervention: MVAC
Number of subjects: 263
Study 9679720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 6
Study 9679720 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6
Study 9679720 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 6
Study 9679720 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 6
Study 9679720 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 6
Study 9679720 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 6
Study 8004882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg twice daily)
Number of subjects: 12
Study 8004882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine and Propranolol (10 mg twice daily and 80 mg twice daily respectively)
Number of subjects: 12
Study 8004882 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily)
Number of subjects: 12
Study 8004882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8004882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine and Propranolol
Number of subjects: 12
Study 31542406 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 100+ sunscreen
Number of subjects: 55
Study 31542406 — intervention group
Group type: COMPARATOR
Intervention: SPF 50+ sunscreen
Number of subjects: 55
Study 30891981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin intervention group
Number of subjects: 60
Study 30891981 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 27484048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 174
Study 27484048 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoids (GC)
Number of subjects: 174
Study 26068086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin (125 μg)
Number of subjects: 652
Study 26068086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 23815766 — intervention group
Group type: EXPERIMENTAL
Intervention: High knowledge and poor self-care
Number of subjects: 612
Study 23815766 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge, depressive symptoms, and perceived control
Number of subjects: 612
Study 23815766 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and anxiety interaction
Number of subjects: 612
Study 23097272 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (50 mg) plus DHA/EPA (420/80 mg)
Number of subjects: 321
Study 23097272 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron plus placebo
Number of subjects: 321
Study 23097272 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus a mixture of DHA and EPA (DHA/EPA)
Number of subjects: 321
Study 23097272 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 321
Study 19398079 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 3965
Study 19398079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3965
Study 16960468 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg dapoxetine
Number of subjects: 340
Study 16960468 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 340
Study 16960468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 16960468 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg dapoxetine and 20 mg paroxetine
Number of subjects: 340
Study 14742620 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective amygdalo-hippocampectomy (SAH) using sylvian approach (9 left/10 right) or transcortical approach (5 left/10 right)
Number of subjects: 34
Study 14742620 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective amygdalo-hippocampectomy (SAH)
Number of subjects: 34
Study 11751735 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 10
Study 9425966 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid sufentanil (12.5 microg)
Number of subjects: 39
Study 9425966 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid lidocaine (75 mg)
Number of subjects: 39
Study 9425966 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid sufentanil (12.5 microg) in women
Number of subjects: 39
Study 9425966 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid lidocaine (75 mg) in women
Number of subjects: 39
Study 8236030 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 11
Study 8236030 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 11
Study 8236030 — intervention group
Group type: EXPERIMENTAL
Intervention: Needles with a diameter of 25G
Number of subjects: 11
Study 8236030 — intervention group
Group type: EXPERIMENTAL
Intervention: Needles with a diameter of 23G
Number of subjects: 11
Study 3442979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilatation during IUD insertion
Number of subjects: 0
Study 3442979 — intervention group
Group type: COMPARATOR
Intervention: No cervical dilatation during IUD insertion
Number of subjects: 0
Study 30658379 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) applied for 1 minute
Number of subjects: 30
Study 30658379 — intervention group
Group type: COMPARATOR
Intervention: 37% phosphoric acid etch followed by bonding
Number of subjects: 30
Study 27639604 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5mg weekly for three months
Number of subjects: 51
Study 27639604 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study 24744165 — intervention group
Group type: EXPERIMENTAL
Intervention: Profiling Ca²⁺ (Pd(Ca))
Number of subjects: 22
Study 24744165 — intervention group
Group type: COMPARATOR
Intervention: Low constant dialysate Ca²⁺ (Ld(Ca), 1.25 mM)
Number of subjects: 22
Study 24744165 — intervention group
Group type: COMPARATOR
Intervention: High constant dialysate Ca²⁺ (Hd(Ca), 2 mM)
Number of subjects: 22
Study 21557796 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (B‐TURP)
Number of subjects: 279
Study 21557796 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (M‐TURP)
Number of subjects: 279
Study 20067426 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 2507
Study 20067426 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 2507
Study 20067426 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthelminthic treatment
Number of subjects: 2507
Study 18717802 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg x kg(‐1) over 20 min followed by an infusion of 0.5 microg x kg(‐1) x h(‐1)) as an adjunct to TIVA (propofol and remifentanil)
Number of subjects: 9
Study 18717802 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg x kg(‐1) over 20 min followed by an infusion of 0.5 microg x kg(‐1) x h(‐1))
Number of subjects: 9
Study 16463843 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 11
Study 16463843 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdialysis
Number of subjects: 11
Study 16463843 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with rCMRglc
Number of subjects: 11
Study 12756022 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (L1)
Number of subjects: 0
Study 12756022 — intervention group
Group type: COMPARATOR
Intervention: Desferrioxamine (DFX)
Number of subjects: 0
Study 10343216 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg hyoscyamine sulfate intravenous (n = 57)
Number of subjects: 116
Study 10343216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 59)
Number of subjects: 116
Study 7473013 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (S)
Number of subjects: 116
Study 7473013 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing with tetracycline (TC) fiber (SF)
Number of subjects: 116
Study 7473013 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of TC fiber (F)
Number of subjects: 116
Study 7473013 — intervention group
Group type: EXPERIMENTAL
Intervention: Two serial applications of TC fiber (FF)
Number of subjects: 116
Study 7473013 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline detection of pathogens: 70.8% Fn, 42.9% Pg, 63.5% Pi, 29.7% Ec, 28.3% Cr, 5.5% Aa.
Number of subjects: 116
Study 1775607 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine added to fluphenazine decanoate and benztropine
Number of subjects: 0
Study 1775607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6946109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.243% NaF dentifrice
Number of subjects: 11
Study 6946109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.40% SnF2 dentifrice
Number of subjects: 11
Study 6946109 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (non-fluoride)
Number of subjects: 11
Study 31778428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led discharge counseling
Number of subjects: 66
Study 31778428 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist-led counseling)
Number of subjects: 66
Study 29462011 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 7 or 9 cm H2O (n = 12)
Number of subjects: 24
Study 29462011 — intervention group
Group type: COMPARATOR
Intervention: Zero PEEP (n = 12)
Number of subjects: 24
Study 26850449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA)
Number of subjects: 8
Study 26850449 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 24643000 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular recanalization (group A)
Number of subjects: 40
Study 24643000 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (group B)
Number of subjects: 40
Study 22146757 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstream use of clotinab with 600-mg clopidogrel pretreatment
Number of subjects: 786
Study 22146757 — intervention group
Group type: COMPARATOR
Intervention: Provisional use of clotinab with 600-mg clopidogrel pretreatment
Number of subjects: 786
Study 22146757 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstream use of clotinab
Number of subjects: 786
Study 22146757 — intervention group
Group type: COMPARATOR
Intervention: Provisional use of clotinab
Number of subjects: 786
Study 22146757 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstream use of clotinab in high-risk population (Killip class ≥II or GRACE score >140)
Number of subjects: 786
Study 20648601 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct switch to adefovir (ADV)
Number of subjects: 35
Study 20648601 — intervention group
Group type: COMPARATOR
Intervention: Overlap of LAM and ADV for 3 months followed by ADV monotherapy
Number of subjects: 35
Study 20648601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 17466071 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical honey along with intralesional injection of glucantime
Number of subjects: 100
Study 17466071 — intervention group
Group type: COMPARATOR
Intervention: Intralesional injection of glucantime alone
Number of subjects: 100
Study 14964629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% applied twice daily with overnight occlusion
Number of subjects: 294